These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19136895)

  • 1. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients.
    van Gurp EA; Schoordijk-Verschoor W; Klepper M; Korevaar SS; Chan G; Weimar W; Baan CC
    Transplantation; 2009 Jan; 87(1):79-86. PubMed ID: 19136895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts.
    Paniagua R; Si MS; Flores MG; Rousvoal G; Zhang S; Aalami O; Campbell A; Changelian PS; Reitz BA; Borie DC
    Transplantation; 2005 Nov; 80(9):1283-92. PubMed ID: 16314797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy.
    Rousvoal G; Si MS; Lau M; Zhang S; Berry GJ; Flores MG; Changelian PS; Reitz BA; Borie DC
    Transpl Int; 2006 Dec; 19(12):1014-21. PubMed ID: 17081232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients.
    Quaedackers ME; Mol W; Korevaar SS; van Gurp EA; van Ijcken WF; Chan G; Weimar W; Baan CC
    Transplantation; 2009 Oct; 88(8):1002-9. PubMed ID: 19855246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.
    Maeshima K; Yamaoka K; Kubo S; Nakano K; Iwata S; Saito K; Ohishi M; Miyahara H; Tanaka S; Ishii K; Yoshimatsu H; Tanaka Y
    Arthritis Rheum; 2012 Jun; 64(6):1790-8. PubMed ID: 22147632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.
    Park HB; Oh K; Garmaa N; Seo MW; Byoun OJ; Lee HY; Lee DS
    Transplantation; 2010 Oct; 90(8):825-35. PubMed ID: 20697326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.
    Fei F; Yu Y; Schmitt A; Rojewski MT; Chen B; Götz M; Döhner H; Bunjes D; Schmitt M
    Br J Haematol; 2009 Jan; 144(2):195-205. PubMed ID: 19016717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
    Tanaka Y; Maeshima K; Yamaoka K
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-class II -DR humanized monoclonal antibody, IMMU-114, blocks allogeneic immune response.
    Park KH; Sawada T; Murakami T; Ishii Y; Yasuo M; Fuchinoue S; Goldenberg DM; Kubota K
    Am J Surg; 2012 Oct; 204(4):527-34. PubMed ID: 22658578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.
    Borie DC; Changelian PS; Larson MJ; Si MS; Paniagua R; Higgins JP; Holm B; Campbell A; Lau M; Zhang S; Flores MG; Rousvoal G; Hawkins J; Ball DA; Kudlacz EM; Brissette WH; Elliott EA; Reitz BA; Morris RE
    Transplantation; 2005 Apr; 79(7):791-801. PubMed ID: 15818321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
    Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
    Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional CD25(bright+) alloresponsive T cells in fully immunosuppressed renal allograft recipients.
    Baan CC; Velthuis JH; van Gurp EA; Mol WM; Klepper M; Ijzermans JN; Weimar W
    Clin Transplant; 2007; 21(1):63-71. PubMed ID: 17302593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK3-STAT pathway blocking benefits in experimental lupus nephritis.
    Ripoll È; de Ramon L; Draibe Bordignon J; Merino A; Bolaños N; Goma M; Cruzado JM; Grinyó JM; Torras J
    Arthritis Res Ther; 2016 Jun; 18(1):134. PubMed ID: 27278657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
    West K
    Curr Opin Investig Drugs; 2009 May; 10(5):491-504. PubMed ID: 19431082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing.
    Conklyn M; Andresen C; Changelian P; Kudlacz E
    J Leukoc Biol; 2004 Dec; 76(6):1248-55. PubMed ID: 15371489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating inflammation with the Janus kinase inhibitor CP-690,550.
    Vijayakrishnan L; Venkataramanan R; Gulati P
    Trends Pharmacol Sci; 2011 Jan; 32(1):25-34. PubMed ID: 21144599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
    LaBranche TP; Jesson MI; Radi ZA; Storer CE; Guzova JA; Bonar SL; Thompson JM; Happa FA; Stewart ZS; Zhan Y; Bollinger CS; Bansal PN; Wellen JW; Wilkie DP; Bailey SA; Symanowicz PT; Hegen M; Head RD; Kishore N; Mbalaviele G; Meyer DM
    Arthritis Rheum; 2012 Nov; 64(11):3531-42. PubMed ID: 22899318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
    Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
    Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational support for an immunoregulatory role of CD3+CD4+CD25+IFN-gamma+ blood lymphocytes in kidney transplant recipients with good long-term graft outcome.
    Daniel V; Naujokat C; Sadeghi M; Weimer R; Renner F; Yildiz S; Opelz G
    Transpl Int; 2008 Jul; 21(7):646-60. PubMed ID: 18298587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells.
    Sewgobind VD; Quaedackers ME; van der Laan LJ; Kraaijeveld R; Korevaar SS; Chan G; Weimar W; Baan CC
    Am J Transplant; 2010 Aug; 10(8):1785-95. PubMed ID: 20626385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.